Safety and Pharmacokinetics of Exebacase in an Infant With Disseminated <i>Staphylococcus aureus</i> Infection
Ganga S. Moorthy, Rachel G. Greenberg, Chi D. Hornik, Cara Cassino, Parviz Ghahramani, Karan R. Kumar, Vance G. Fowler, Michael Cohen‐Wolkowiez
Abstract
Exebacase, an antistaphylococcal lysin produced from a bacteriophage-encoded gene, is a promising adjunctive therapy for severe methicillin-resistant Staphylococcus aureus infections. We describe the first infant to receive exebacase, dosing, and pharmacokinetics. Exebacase may be safe and efficacious in children; however, further clinical trials are needed to optimize dosing.
Topics & Concepts
MedicineDosingStaphylococcus aureusPharmacokineticsStaphylococcal infectionsAntibioticsLysinClinical trialIntensive care medicineBacteriophageMicrobiologyPharmacologyInternal medicineBacteriaGeneBiologyGeneticsBiochemistryEscherichia coliAntimicrobial Resistance in StaphylococcusStreptococcal Infections and TreatmentsInfections and bacterial resistance